JP2018111711A - リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩 - Google Patents
リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩 Download PDFInfo
- Publication number
- JP2018111711A JP2018111711A JP2018043874A JP2018043874A JP2018111711A JP 2018111711 A JP2018111711 A JP 2018111711A JP 2018043874 A JP2018043874 A JP 2018043874A JP 2018043874 A JP2018043874 A JP 2018043874A JP 2018111711 A JP2018111711 A JP 2018111711A
- Authority
- JP
- Japan
- Prior art keywords
- riboflavin
- phosphate
- physiologically acceptable
- acceptable salt
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title claims abstract description 173
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 229960002477 riboflavin Drugs 0.000 title claims abstract description 87
- 235000019192 riboflavin Nutrition 0.000 title claims abstract description 85
- 239000002151 riboflavin Substances 0.000 title claims abstract description 85
- 150000003839 salts Chemical class 0.000 title claims abstract description 20
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 title claims abstract description 19
- 229950001574 riboflavin phosphate Drugs 0.000 title claims abstract description 16
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 17
- 230000004936 stimulating effect Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 26
- 230000012010 growth Effects 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 73
- 241000894006 Bacteria Species 0.000 abstract description 52
- 235000018417 cysteine Nutrition 0.000 abstract description 28
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 28
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 abstract description 20
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract description 20
- 230000009286 beneficial effect Effects 0.000 abstract description 12
- 235000015872 dietary supplement Nutrition 0.000 abstract description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 abstract description 10
- 239000001301 oxygen Substances 0.000 abstract description 10
- 235000019722 synbiotics Nutrition 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 238000012423 maintenance Methods 0.000 abstract description 3
- 241000605980 Faecalibacterium prausnitzii Species 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 description 29
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 29
- 229940029339 inulin Drugs 0.000 description 29
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 27
- 229960002433 cysteine Drugs 0.000 description 27
- 238000009472 formulation Methods 0.000 description 17
- 239000008187 granular material Substances 0.000 description 17
- 235000015099 wheat brans Nutrition 0.000 description 17
- 239000006041 probiotic Substances 0.000 description 14
- 235000018291 probiotics Nutrition 0.000 description 14
- 229920002261 Corn starch Polymers 0.000 description 13
- 239000008120 corn starch Substances 0.000 description 13
- 239000008188 pellet Substances 0.000 description 13
- 235000013406 prebiotics Nutrition 0.000 description 12
- 239000012080 ambient air Substances 0.000 description 10
- 230000037406 food intake Effects 0.000 description 9
- 230000000529 probiotic effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 229920000294 Resistant starch Polymers 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 5
- 229940107187 fructooligosaccharide Drugs 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000021254 resistant starch Nutrition 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 240000008620 Fagopyrum esculentum Species 0.000 description 3
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229940103141 riboflavin 100 mg Drugs 0.000 description 3
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 239000004228 Riboflavin-5'-Phosphate Substances 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241001227086 Anaerostipes Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241001608234 Faecalibacterium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023138 Jaundice neonatal Diseases 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 description 1
- 241000605947 Roseburia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 206010047612 Vitamin B2 deficiency Diseases 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- 241000186569 [Clostridium] leptum Species 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000007590 ariboflavinosis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- -1 casciton Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000005489 dwarf bean Nutrition 0.000 description 1
- 241001233061 earthworms Species 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 244000297694 fish poison bean Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000024717 negative regulation of secretion Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000004223 riboflavin deficiency Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- 235000020125 yoghurt-based beverage Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【解決手段】動物の胃腸管においてフィーカリバクテリウムプラウスニッツィイを選択的に刺激するための食品組成物、医薬組成物、食品又は健康補助食品の製造のためのリボフラビン、リン酸リボフラビン又は生理学上許容されるその塩の使用の提供。また、リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩、及びシステインとともに調合された生きた有益なブチレート生成嫌気性細菌を含むシンバイオティクス組成物の提供。
【選択図】なし
Description
リボフラビンが腸のフィーカリバクテリウム プラウスニッツィイの個数に与える影響を調査するため、ヒト介入試験を実施した。志願者8名の群(体重60〜90kg)は、リボフラビンのサプリメント100mgを1日1回、14日間経口摂取するよう求められた。
好気条件下で少なくとも24時間安定である生きたフィーカリバクテリウムを備える製剤を生成するため、一連の実験を異なる成分の組み合わせで実施した。フィーカリバクテリウムは、ブロス培地中で一晩増殖させ、遠心分離し、ペレットを嫌気性リン酸緩衝食塩水(PBS)にて洗浄し再び遠心分離を行った。ペレットは、表1に示す成分を含有するPBSと混合した。混合物は−20℃で凍結し、次に凍結乾燥した。
・可逆性酸化還元反応を持つ、抗酸化剤のシステイン及びリボフラビンの存在。この保護効果は、クエルセチン又はアスコルビン酸のような他の抗酸化剤では観察されなかった。クエルセチンは不可逆的に酸化され、アスコルビン酸は水分が存在すると安定しないため、これらは保護効果を持たなかった。
・抗酸化性の酸化還元媒介剤により酸素透過から良好に保護するためには、細粒が小型であること又は例えばイヌリンといった凍結保存剤(cryo−preservant)でコーティングすることが好ましい。イヌリンでコーティングされた場合にのみ、小麦ふすま又はコーンスターチの追加が有効である。また、イヌリンは小麦ふすま又はコーンスターチより水分を引き付けない。
細菌の培養
F.プラウスニッツィイ株A2−165(DSM17677)を、酵母エキス、カシトン、脂肪酸及びグルコース(YCFAG)寒天培地上でサンプル10μlを培養することで、グリセロールストック(−80℃)から戻した。培養物は、37℃における、H210%、CO210%及びN280%(v/v)混合ガスを備える嫌気性のテント(tent)内の、YCFAG培地上で、培養及び通常通りの維持がなされた。種培養液は、F.プラウスニッツィイ株の単一コロニーをYCFAG培養液5mlに播種し、600nm(A600)の光学密度(OD)が0.8以下となるまで12時間〜16時間培養して得た。種培養液1mlを新鮮YCFAG培地50mlに播種した(2%v/vで播種)。培養物は、ODA600が0.8±0.2以下に到達するまで12時間〜16時間培養した。細胞は、17℃10分間、2700gで遠心分離し、採取した。ペレットは、殺菌した嫌気性食塩水(0.85%食塩と0.05%システイン)で1度洗浄した。
製剤手順
ステップ1に準じて得られた細菌ペレット(5×108〜2×109の細菌を含有)を、イヌリン10%(w/v)及びシステイン16.5mMを含有する溶液0.4mlに懸濁した。ペレットを再懸濁した後、リボフラビンの貯蔵液0.2ml(16.5mM)を追加した。完全に混合した後、小麦ふすま0.5gとコーンスターチ0.9gを追加し、その結果生じたスラリーを湿式造粒した。湿潤細粒は、少なくとも3時間、−20℃で凍結した。凍結後、細粒を少なくとも3時間凍結乾燥した。
ステップ1に準じて得られた細菌ペレットを、トレハロース10%及びシステイン16.5mMを含有する溶液0.4mlに懸濁した。ペレットを再懸濁した後、リボフラビンの貯蔵液0.2ml(16.5mM)を追加した。完全に混合した後、小麦ふすま0.5gとコーンスターチ0.9gを追加し、その結果生じたスラリーを湿式造粒した。湿潤細粒は、少なくとも3時間、−20℃で凍結した。凍結後、細粒を少なくとも3時間凍結乾燥した。
ステップ1に準じて得られた細菌ペレットを、イヌリン又はトレハロース10%及びシステイン16.5mMを含有する溶液1.6mlに懸濁した。溶液は、システインの追加前にN2でパージした。ペレットを再懸濁した後、リボフラビンの貯蔵液0.2ml(16.5mM)を追加した。完全に混合した後、その結果生じたスラリーを少なくとも3時間、−20℃で凍結した。凍結後、細粒を少なくとも3時間凍結乾燥した。
ステップ1に準じて得られた細菌ペレットを、システイン16.5mMの溶液0.4mlに懸濁した。ペレットを再懸濁した後、リボフラビンの貯蔵液0.2ml(16.5mM)を追加した。完全に混合した後、その結果生じたスラリーを少なくとも3時間、−20℃で凍結した。凍結後、細粒を少なくとも3時間凍結乾燥した。
ステップ1に準じて得られた細菌ペレット(5×108〜2×109の細菌を含有)をイヌリン10%(w/v)とシステイン16.5mMを含有する溶液0.4mlに懸濁した。ペレットを再懸濁した後、リボフラビンの貯蔵液0.2ml(100mM)を追加した。完全に混合した後、小麦ふすま0.5gとコーンスターチ0.9gを追加し、その結果生じたスラリーを湿式造粒した。湿潤細粒は、少なくとも3時間、−20℃で凍結した。凍結後、細粒を少なくとも3時間凍結乾燥した。
安定性及び生存率試験の手順
ステップ2に準じて得られた凍結乾燥した細粒は、周囲の好気的条件の下、気密容器に貯蔵した。安定性及び生存率試験のため、細粒を規定の期間、最大24時間、周囲空気に曝露した。好気への曝露後、細粒を嫌気性のテント(tent)下で嫌気的に処理した。細粒を希釈し、システイン0.05%が補充された無酸素リン酸緩衝食塩水(pH7.2)で水戻しし、10倍希釈系列をYCFAG寒天培地に置いた。コロニー形成単位は、37℃で24時間培養した後、寒天培地上に形成されたコロニーを計測することで定量した。
(付記1)
動物の胃腸管においてフィーカリバクテリウム プラウスニッツィイ(Faecalibacterium prausnitzii)を選択的に刺激するための食品組成物、医薬組成物、食品又は健康補助食品の製造のためのリボフラビン、リン酸リボフラビン又は生理学上許容されるその塩の使用であって、
リボフラビンは、体重1kg当たり1日0.01〜2mgの量で使用される、使用。
前記動物は哺乳類であり、好ましくはヒト対象である、付記1に記載の使用。
前記ヒト対象は、炎症性の胃腸疾患、特にクローン病に罹患している、付記2に記載の使用。
リボフラビンは、体重1kg当たり1日0.1〜2mgの量で使用される、付記1〜3のいずれか1つに記載の使用。
リボフラビンは、少なくとも3日間、好ましくは少なくとも7日間、より好ましくは少なくとも10日間投与される、付記1〜4のいずれか1つに記載の使用。
リボフラビンは、1日1回の用量として投与される、付記1〜5のいずれか1つに記載の使用。
フィーカリバクテリウム プラウスニッツィイのプレバイオティクスとしての、リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩の使用。
フィーカリバクテリウム プラウスニッツィイを、それを必要とする動物の胃腸管において選択的に刺激する方法であって、
リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩を、前記胃腸管においてフィーカリバクテリウム プラウスニッツィイの増殖を選択的に刺激するのに有効な量で、前記動物に投与することを含む、方法。
シンバイオティクス組成物であって、
(i)生きている有益なブチレート生成嫌気性細菌、
(ii)前記組成物の総乾燥重量に基づき少なくとも0.05%の量の、リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩、及び、
(iii)システイン、
を含む、シンバイオティクス組成物。
リボフラビン、リン酸リボフラビン又はその塩は、前記組成物の総乾燥重量に基づき少なくとも1%、好ましくは少なくとも2%の量で存在する、付記9に記載の組成物。
システインは、前記組成物の総乾燥重量に基づき0.05〜2%の量で存在する、付記9又は10に記載の組成物。
イヌリン又はイヌリンタイプのフラクトオリゴ糖を、好ましくは前記組成物の総乾燥重量に基づき2〜10%の量で、さらに含む、付記9〜11のいずれか1つに記載の組成物。
充填剤を、好ましくは前記組成物の総乾燥重量に基づき40〜65%量で、さらに含む、付記9〜12のいずれか1つに記載の組成物。
前記ブチレート生成嫌気性細菌は、ファーミキューテス(Firmicutes)門、好ましくはクロストリジウムレプタム(Clostridium leptum)系統発生グループのメンバーである、付記9〜13のいずれか1つに記載の組成物。
前記ブチレート生成嫌気性細菌は、フィーカリバクテリウム プラウスニッツィイである、付記14に記載の組成物。
フィーカリバクテリウム プラウスニッツィイ細菌を周囲空気への曝露による有害な影響から保護するための方法であって、当該方法は、
フィーカリバクテリウム プラウスニッツィイ細菌を、
(i)リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩、
(ii)システイン、
(iii)イヌリン、
(iv)コーンスターチ、及び、
(v)小麦ふすま又はソバふすま、
を含む組成物中に調剤することを含み、
前記調剤は、前記細菌、前記リボフラビン及び前記システインを含有する細粒を提供することと、前記コーンスターチ及びふすまを追加する前に前記細粒をイヌリンでコーティングすることとを含む、方法。
Claims (7)
- 動物の胃腸管におけるフィーカリバクテリウム プラウスニッツィイ(Faecalibacterium prausnitzii)の増殖を選択的に刺激するのに有効な量で、前記動物にリボフラビン、リン酸リボフラビン又は生理学上許容されるその塩を投与することを含む、動物の胃腸管におけるフィーカリバクテリウム プラウスニッツィイを選択的に刺激するための方法における使用のためのリボフラビン、リン酸リボフラビン又は生理学上許容されるその塩。
- 前記動物は、ヒト、ペット又は家畜である、
ことを特徴とする請求項1に記載のリボフラビン、リン酸リボフラビン又は生理学上許容されるその塩。 - 胃腸管におけるフィーカリバクテリウム プラウスニッツィイの増殖を維持、支援又は刺激するのに有効な量で、必要とするヒト対象にリボフラビンが投与することを含む、炎症性の胃腸障害に関連する症状を予防、治療又は低減するための方法における使用のためのリボフラビン。
- 前記炎症性の胃腸障害は、炎症性の胃腸疾患である、
ことを特徴とする請求項3に記載のリボフラビン。 - 前記炎症性の胃腸疾患は、クローン病及び潰瘍性結腸炎である、
ことを特徴とする請求項4に記載のリボフラビン。 - リボフラビンは、体重1kg当たり1日0.1〜1000mg、好ましくは体重1kg当たり1日1〜100mgの用量で投与される、
ことを特徴とする請求項1乃至5のいずれか1項に記載のリボフラビン、リン酸リボフラビン又は生理学上許容されるその塩。 - リボフラビンは、少なくとも3日間、好ましくは少なくとも7日間、より好ましくは少なくとも10日間投与される、
ことを特徴とする請求項1乃至6のいずれか1項に記載のリボフラビン、リン酸リボフラビン又は生理学上許容されるその塩。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12190948 | 2012-11-01 | ||
EP12190948.5 | 2012-11-01 | ||
US201261728811P | 2012-11-21 | 2012-11-21 | |
US61/728,811 | 2012-11-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015540630A Division JP2015535280A (ja) | 2012-11-01 | 2013-11-01 | 胃腸管において有益な細菌を刺激する方法及び組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018111711A true JP2018111711A (ja) | 2018-07-19 |
Family
ID=47148630
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015540630A Pending JP2015535280A (ja) | 2012-11-01 | 2013-11-01 | 胃腸管において有益な細菌を刺激する方法及び組成物 |
JP2018043874A Pending JP2018111711A (ja) | 2012-11-01 | 2018-03-12 | リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015540630A Pending JP2015535280A (ja) | 2012-11-01 | 2013-11-01 | 胃腸管において有益な細菌を刺激する方法及び組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20150283144A1 (ja) |
EP (2) | EP3345606A1 (ja) |
JP (2) | JP2015535280A (ja) |
AU (1) | AU2013338774B2 (ja) |
BR (1) | BR112015009975A2 (ja) |
WO (1) | WO2014070014A1 (ja) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
CN108771687A (zh) | 2012-02-29 | 2018-11-09 | 伊西康内外科公司 | 微生物区系的组合物及与其相关的方法 |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
FI127483B (en) * | 2014-06-11 | 2018-07-13 | Gut Guide Oy | Microbial marker for celiac disease and related product |
CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
LT3065748T (lt) | 2014-12-23 | 2018-03-12 | 4D Pharma Research Limited | Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui |
HUE037476T2 (hu) | 2014-12-23 | 2018-08-28 | 4D Pharma Res Ltd | Pirin polipeptid és immunmodulálás |
TWI759260B (zh) | 2015-01-02 | 2022-04-01 | 美商梅拉洛伊卡公司 | 多元補充品組成物 |
TWI790189B (zh) | 2015-01-02 | 2023-01-21 | 美商梅拉洛伊卡公司 | 細菌組成物 |
US10137164B2 (en) | 2015-01-02 | 2018-11-27 | Melaleuca, Inc. | Dietary supplement compositions |
EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
DK3297644T3 (da) | 2015-05-22 | 2022-04-11 | Univ Arizona State | Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer |
ES2833349T3 (es) * | 2015-06-09 | 2021-06-15 | Univ Minnesota | Procedimientos para detectar el riesgo de tener una infección de torrente sanguíneo |
LT3650033T (lt) | 2015-06-15 | 2022-04-11 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterinius kamienus |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3636272A1 (en) | 2015-06-15 | 2020-04-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
RS59308B1 (sr) | 2015-06-15 | 2019-10-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
GB201519087D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | Method for adaption |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB2561748B (en) | 2015-11-20 | 2019-05-08 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
US11564667B2 (en) | 2015-12-28 | 2023-01-31 | New York University | Device and method of restoring microbiota of newborns |
TW201733601A (zh) | 2016-03-04 | 2017-10-01 | 4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
CA3026414A1 (en) * | 2016-06-01 | 2017-12-07 | Crestovo Holdings Llc | Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders |
CN109561725A (zh) * | 2016-06-10 | 2019-04-02 | N·V·努特里奇亚 | 患过敏症的风险和用于降低该风险的营养物 |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
CN110831606A (zh) | 2017-04-05 | 2020-02-21 | 克雷斯顿沃控股公司 | 治疗帕金森氏病(pd)和相关疾病的组合物和方法 |
US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
MA48940A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
KR20200010450A (ko) | 2017-06-02 | 2020-01-30 | 굿것 에스.엘. | 장내 세균 불균형의 치료에 사용하기 위한 포도 껍질 |
DK3804737T3 (da) | 2017-06-14 | 2022-07-25 | 4D Pharma Res Ltd | Sammensætninger omfattende bakteriestammer |
MD3638271T2 (ro) | 2017-06-14 | 2021-03-31 | 4D Pharma Res Ltd | Compoziții cuprizând tulpini bacteriene |
AU2018313766A1 (en) | 2017-08-07 | 2020-02-20 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
BR112020008194A2 (pt) | 2017-11-03 | 2020-10-06 | Dsm Ip Assets B.V. | sistema de entrega inovador |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
KR20210087927A (ko) | 2018-08-29 | 2021-07-13 | 디에스엠 아이피 어셋츠 비.브이. | 장 건강 개선을 위한 제형 |
WO2020069280A1 (en) | 2018-09-27 | 2020-04-02 | Crestovo Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
WO2020161089A1 (en) * | 2019-02-04 | 2020-08-13 | Dsm Ip Assets B.V. | Therapeutic combinations and compositions for the treatment of inflammatory bowel disease (ii) |
BR112021015088A2 (pt) * | 2019-02-04 | 2021-10-05 | Dsm Ip Assets B.V. | Combinações terapêuticas e composições para o tratamento de doença inflamatória intestinal |
KR20220139955A (ko) | 2020-02-12 | 2022-10-17 | 디에스엠 아이피 어셋츠 비.브이. | 장으로의 산화방지제의 직접 전달 |
CN116367823A (zh) | 2020-10-28 | 2023-06-30 | 帝斯曼知识产权资产管理有限公司 | 直接递送维生素以抑制微生物病原体 |
WO2022090335A1 (en) | 2020-10-28 | 2022-05-05 | Dsm Ip Assets B.V. | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59132884A (ja) * | 1983-01-20 | 1984-07-31 | Dai Ichi Seiyaku Co Ltd | ビフイズス菌増殖促進組成物 |
JP2004059488A (ja) * | 2002-07-29 | 2004-02-26 | Asahi Food & Healthcare Ltd | 乳酸菌整腸組成物および食品 |
JP2006507283A (ja) * | 2002-10-23 | 2006-03-02 | クエルセジーン ホールディングス エルエルシー | 抗酸化組成物 |
WO2011060123A1 (en) * | 2009-11-12 | 2011-05-19 | Nestec S.A. | Nutritional composition for promoting gut microbiota balance and health |
WO2012076739A1 (es) * | 2010-12-07 | 2012-06-14 | Consejo Superior De Investigaciones Científicas C.S.I.C. | Bifidobacterium CECT 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE442143T1 (de) * | 2001-03-21 | 2009-09-15 | Eisai R&D Man Co Ltd | Reduziertes vitamin b2 enthaltende arzneimittel |
ES2235642B2 (es) * | 2003-12-18 | 2006-03-01 | Gat Formulation Gmbh | Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos. |
WO2011086172A1 (en) | 2010-01-14 | 2011-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs) |
NL2004201C2 (en) * | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
-
2013
- 2013-11-01 EP EP18157821.2A patent/EP3345606A1/en not_active Withdrawn
- 2013-11-01 EP EP13795881.5A patent/EP2914135A1/en not_active Withdrawn
- 2013-11-01 BR BR112015009975A patent/BR112015009975A2/pt not_active Application Discontinuation
- 2013-11-01 WO PCT/NL2013/050781 patent/WO2014070014A1/en active Application Filing
- 2013-11-01 US US14/439,882 patent/US20150283144A1/en not_active Abandoned
- 2013-11-01 AU AU2013338774A patent/AU2013338774B2/en not_active Ceased
- 2013-11-01 JP JP2015540630A patent/JP2015535280A/ja active Pending
-
2018
- 2018-03-09 US US15/916,704 patent/US20180207165A1/en not_active Abandoned
- 2018-03-12 JP JP2018043874A patent/JP2018111711A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59132884A (ja) * | 1983-01-20 | 1984-07-31 | Dai Ichi Seiyaku Co Ltd | ビフイズス菌増殖促進組成物 |
JP2004059488A (ja) * | 2002-07-29 | 2004-02-26 | Asahi Food & Healthcare Ltd | 乳酸菌整腸組成物および食品 |
JP2006507283A (ja) * | 2002-10-23 | 2006-03-02 | クエルセジーン ホールディングス エルエルシー | 抗酸化組成物 |
WO2011060123A1 (en) * | 2009-11-12 | 2011-05-19 | Nestec S.A. | Nutritional composition for promoting gut microbiota balance and health |
WO2012076739A1 (es) * | 2010-12-07 | 2012-06-14 | Consejo Superior De Investigaciones Científicas C.S.I.C. | Bifidobacterium CECT 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas |
Non-Patent Citations (1)
Title |
---|
THE ISME JOURNAL, FEB 2012, VOL.6, P.1578-1585, JPN6017034911 * |
Also Published As
Publication number | Publication date |
---|---|
EP3345606A1 (en) | 2018-07-11 |
JP2015535280A (ja) | 2015-12-10 |
WO2014070014A1 (en) | 2014-05-08 |
AU2013338774B2 (en) | 2017-03-02 |
EP2914135A1 (en) | 2015-09-09 |
AU2013338774A1 (en) | 2015-05-21 |
BR112015009975A2 (pt) | 2017-07-11 |
US20150283144A1 (en) | 2015-10-08 |
US20180207165A1 (en) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018111711A (ja) | リボフラビン、リン酸リボフラビン又は生理学上許容されるその塩 | |
Vasiljevic et al. | Probiotics—from Metchnikoff to bioactives | |
Ebel et al. | Impact of probiotics on risk factors for cardiovascular diseases. A review | |
US20190070229A1 (en) | Composition comprising a lactic acid bacteria for preventing and treating vaginosis and the use thereof | |
JP5577020B2 (ja) | 代謝活性を有する微生物及びその製造方法 | |
TWI594758B (zh) | 包含雙歧桿菌的組合物、其製備方法及其用途 | |
EP2459203B1 (en) | Lactic acid bacteria and bifidobacteria for treating endotoxemia | |
US20200345791A1 (en) | Probiotic Bacterial Strains That Produce Short Chain Fatty Acids And Compositions Comprising Same | |
EP3808357A1 (en) | Composition and uses thereof | |
CN111372477B (zh) | 在含有gos的培养基中预调理的益生菌及其用途 | |
Rovinaru et al. | Application of microencapsulated synbiotics in fruit-based beverages | |
Cuvas-Limón et al. | Aloe vera and probiotics: a new alternative to symbiotic functional foods | |
JP2013538827A (ja) | 腎機能を増強させるための組成物および方法 | |
Sip et al. | Probiotics and prebiotics | |
KR20220018964A (ko) | 더 큰 내약성 및 연장된 저장 수명을 위한 미생물 조성물 및 방법 | |
Konuray et al. | Antimicrobial Effect of Probiotics, Prebiotics, and Synbiotics | |
Gupta et al. | Synbiotics: promoting gastrointestinal health | |
Ying et al. | Probiotics and prebiotics | |
Khosravi et al. | Synbiosis between Enterococcus faecium DSM 3530 and Fructan Compounds of Different Degree of Polymeriza tion: a Preliminary In vitro Assay in a Condition Simulated Chicken Caecum | |
Paliy et al. | Influence of various prebiotic components on the main growth indicators of probiotic bacteria | |
CN116507718A (zh) | 稳定的乳酸菌组合物 | |
Biedrzycka | Microecosystem of the large intestine as a target-place for probiotics and prebiotics used as functional compounds of diet-a review. | |
Khan et al. | Epistemology of Probiotics | |
Gaikwad et al. | PROBIOTICS AND ITS EFFECTS ON GASTROINTESTINAL INFECTIONS: AN OVERVIEW | |
JP2023179810A (ja) | ラクトコッカス・ラクチス、ラクトバチルス属に属する微生物、又はこれらの混合微生物を含有する生菌剤及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190517 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190816 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191015 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200309 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200623 |